Modeled Survival Gains of Patients with Cystic Fibrosis (CF) Aged ≥12 Years Homozygous for the F508dEL Mutation Treated with the CF Transmembrane Conductance Regulator Modulator (CFTRM) Tezacaftor/Ivacaftor (TEZ/IVA)
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.1392
https://www.valueinhealthjournal.com/article/S1098-3015(18)31698-X/fulltext
Section Title :
Section Order :
642
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31698-X&doi=10.1016/j.jval.2018.04.1392